Glyciphage P 15 mg/500 mg Tablet SR is a combination oral antidiabetic medication containing Pioglitazone 15 mg and Metformin 500 mg in a sustained-release formulation. It is indicated for the management of type 2 diabetes mellitus, particularly in patients who have inadequate glycemic control with diet and exercise alone. Pioglitazone, a thiazolidinedione, improves insulin sensitivity by acting as a selective agonist of the peroxisome proliferator-activated receptor gamma (PPAR-γ), thereby enhancing peripheral glucose uptake and utilization. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity, contributing to better glycemic control. The sustained-release formulation allows for a gradual release of the active ingredients, promoting improved gastrointestinal tolerability and enhanced patient compliance through reduced dosing frequency. Glyciphage P is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. Caution is advised in patients with renal or hepatic impairment, congestive heart failure, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, weight gain, and edema. Regular monitoring of blood glucose levels, renal function, and liver enzymes is recommended to ensure safety and efficacy during therapy.